ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference


Geneva, Switzerland, 05 April, 2016 - ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye, MD, PhD, Chief Executive Officer & Co-Founder of ObsEva, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:00 a.m. ET at the Westin Grand Central Hotel in New York City.

A live audio webcast of the presentation will be available on the company's website, www.ObsEva.com. Following conclusion of the event, a replay of the presentation will be available on the company's website for at least 90 days.

- ends -

About ObsEva

ObsEva is a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women's reproductive therapeutics. For more information, please visit www.ObsEva.com.

MEDIA CONTACT IR CONTACT
Gretchen Schweitzer or Blair Atkinson  Amy Conrad
MacDougall Biomedical Communications Juniper Point
Direct: +49 172 861 8540 or +1 812 454 6257 +1 858 914 1962
Main: +49 89 2424 3494 or +1 781 235 3060 Amy@juniper-point.com
gschweitzer@macbiocom.com  
   
COMPANY CONTACT  
Delphine Renaud  
ObsEva CEO Office  
+41 22 552 1550  
delphine.renaud@obseva.ch  

Attachments

Press release (PDF)